Behçet’s Disease in Children: Diagnostic and Management Challenges

References

• Yildiz M, Koker O. Pediatric Behcet’s disease - clinical aspects and current concepts. Eur J Rheumatol. 2019;5:1–10.
   Google Scholar
• Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet’s disease. Front Immunol. 2019;10:665. doi:10.3389/fimmu.2019.00665
   PubMed Web of Science ®Google Scholar
• Greco A, De Virgilio A, Ralli M, et al. Behcet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567–575. doi:10.1016/j.autrev.2017.12.006
   PubMed Web of Science ®Google Scholar
• Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behcet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54(3):213–220. doi:10.1034/j.1399-0039.1999.540301.x
   PubMedGoogle Scholar
• Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13(1):57–65. doi:10.1080/1744666X.2016.1205486
   PubMed Web of Science ®Google Scholar
• Madanat WY, Alawneh KM, Smadi MM, et al. The prevalence of Behcet’s disease in the north of Jordan: a hospital-based epidemiological survey. Clin Exp Rheumatol. 2017;35 Suppl 108(6):51–54.
   PubMed Web of Science ®Google Scholar
• Bas Y, Seckin HY, Kalkan G, et al. Investigation of Behcet’s disease and recurrent aphthous stomatitis frequency: the highest prevalence in Turkey. Balkan Medl J. 2016;33(4):390–395. doi:10.5152/balkanmedj.2016.15101
   PubMed Web of Science ®Google Scholar
• Cho SB, Cho S, Bang D. New insights in the clinical understanding of Behcet’s disease. Yonsei Med J. 2012;53(1):35–42. doi:10.3349/ymj.2012.53.1.35
   PubMed Web of Science ®Google Scholar
• Akkoc N. Update on the epidemiology, risk factors and disease outcomes of Behcet’s disease. Best Pract Res Clin Rheumatol. 2018;32(2):261–270. doi:10.1016/j.berh.2018.08.010
   PubMed Web of Science ®Google Scholar
• Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology. 2012;51(5):887–900. doi:10.1093/rheumatology/ker428
   PubMed Web of Science ®Google Scholar
• de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–1296. doi:10.1002/art.24642
   PubMed Web of Science ®Google Scholar
• Leccese P, Alpsoy E. Behcet’s disease: an overview of etiopathogenesis. Front Immunol. 2019;10:1067. doi:10.3389/fimmu.2019.01067
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet’s disease. Autoimmun Rev. 2012;11(10):687–698. doi:10.1016/j.autrev.2011.11.026
   PubMed Web of Science ®Google Scholar
• Kone-Paut I. Behcet’s disease in children, an overview. Pediatr Rheumatol Online J. 2016;14(1):10. doi:10.1186/s12969-016-0070-z
   PubMed Web of Science ®Google Scholar
• Karincaoglu Y, Borlu M, Toker SC, et al. Demographic and clinical properties of juvenile-onset Behcet’s disease: a controlled multicenter study. J Am Acad Dermatol. 2008;58(4):579–584. doi:10.1016/j.jaad.2007.10.452
   PubMed Web of Science ®Google Scholar
• Gallizzi R, Pidone C, Cantarini L, et al. A national cohort study on pediatric Behcet’s disease: cross-sectional data from an Italian registry. Pediatr Rheumatol. 2017;15(1):84. doi:10.1186/s12969-017-0213-x
   PubMed Web of Science ®Google Scholar
• Gul A. Genetics of Behcet’s disease: lessons learned from genomewide association studies. Curr Opin Rheumatol. 2014;26(1):56–63. doi:10.1097/BOR.0000000000000003
   PubMed Web of Science ®Google Scholar
• Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–706. doi:10.1038/ng.624
   PubMed Web of Science ®Google Scholar
• Hou S, Yang Z, Du L, et al. Identification of a susceptibility locus in STAT4 for Behcet’s disease in Han Chinese in a genome-wide association study. Arthritis Rheum. 2012;64(12):4104–4113. doi:10.1002/art.37708
   PubMed Web of Science ®Google Scholar
• Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. Nat Genet. 2010;42(8):698–702. doi:10.1038/ng.625
   PubMed Web of Science ®Google Scholar
• Kone-Paut I, Yurdakul S, Bahabri SA, et al. Clinical features of Behcet’s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132(4):721–725. doi:10.1016/S0022-3476(98)70368-3
   PubMed Web of Science ®Google Scholar
• Kaneko F, Oyama N, Yanagihori H, Isogai E, Yokota K, Oguma K. The role of streptococcal hypersensitivity in the pathogenesis of Behcet’s Disease. Eur J Dermatol. 2008;18(5):489–498.
   PubMed Web of Science ®Google Scholar
• Yokota K, Hayashi S, Fujii N, et al. Antibody response to oral streptococci in Behcet’s disease. Microbiol Immunol. 1992;36(8):815–822. doi:10.1111/j.1348-0421.1992.tb02083.x
   PubMed Web of Science ®Google Scholar
• Consolandi C, Turroni S, Emmi G, et al. Behcet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):269–276. doi:10.1016/j.autrev.2014.11.009
   PubMed Web of Science ®Google Scholar
• Coit P, Mumcu G, Ture-Ozdemir F, et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet’s disease. Clin Immunol. 2016;169:28–35. doi:10.1016/j.clim.2016.06.002
   PubMed Web of Science ®Google Scholar
• Bulur I, Onder M. Behcet disease: new aspects. Clin Dermatol. 2017;35(5):421–434. doi:10.1016/j.clindermatol.2017.06.004
   PubMed Web of Science ®Google Scholar
• McGonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H. ‘MHC-I-opathy’-unified concept for spondyloarthritis and Behcet disease. Nat Rev Rheumatol. 2015;11(12):731–740. doi:10.1038/nrrheum.2015.147
   PubMed Web of Science ®Google Scholar
• Giza M, Koftori D, Chen L, Bowness P. Is Behcet’s disease a ‘class 1-opathy’? The role of HLA-B*51 in the pathogenesis of Behcet’s disease. Clin Exp Immunol. 2018;191(1):11–18. doi:10.1111/cei.13049
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Ito M, Nakagawa A, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology. 2000;36(4):362–371. doi:10.1046/j.1365-2559.2000.00859.x
   PubMed Web of Science ®Google Scholar
• Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet’s disease. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S19–24.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519–531. doi:10.1038/nri3024
   PubMed Web of Science ®Google Scholar
• Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C. Behcet’s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Immunol. 2019;10:1085. doi:10.3389/fimmu.2019.01085
   PubMed Web of Science ®Google Scholar
• Becatti M, Emmi G, Silvestri E, et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behcet disease. Circulation. 2016;133(3):302–311. doi:10.1161/CIRCULATIONAHA.115.017738
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Takahashi H, Satoh T, et al. Natural killer cells control a T-helper 1 response in patients with Behcet’s disease. Arthritis Res Ther. 2010;12(3):R80. doi:10.1186/ar3005
   PubMed Web of Science ®Google Scholar
• Freysdottir J, Hussain L, Farmer I, Lau SH, Fortune F. Diversity of gammadelta T cells in patients with Behcet’s disease is indicative of polyclonal activation. Oral Dis. 2006;12(3):271–277. doi:10.1111/j.1601-0825.2005.01185.x
   PubMed Web of Science ®Google Scholar
• Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum. 2013;43(3):352–361. doi:10.1016/j.semarthrit.2013.05.003
   PubMed Web of Science ®Google Scholar
• Nian H, Shao H, O’Brien RL, Born WK, Kaplan HJ, Sun D. Activated γδ T cells promote the activation of uveitogenic T cells and exacerbate EAU development. Invest Ophthalmol Vis Sci. 2011;52(8):5920–5927. doi:10.1167/iovs.10-6758
   PubMed Web of Science ®Google Scholar
• Deniz R, Tulunay-Virlan A, Ture Ozdemir F, et al. Th17- inducing conditions lead to in vitro activation of both Th17 and Th1 responses in Behcet’s disease. Immunol Invest. 2017;46(5):518–525. doi:10.1080/08820139.2017.1306865
   PubMed Web of Science ®Google Scholar
• Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL- 21 in modulating TH17 and regulatory T cells in Behcet disease. J Allergy Clin Immunol. 2011;128(3):655–664. doi:10.1016/j.jaci.2011.05.029
   PubMed Web of Science ®Google Scholar
• Kim J, Park JA, Lee EY, Lee YJ, Song YW, Lee EB. Imbalance of Th17 to Th1 cells in Behcet’s disease. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S16–9.
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857–863. doi:10.1038/ni.1767
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Tuzun E, Icoz S, et al. Interleukin-6 in neuro-Behcet’s disease: association with disease subsets and long-term outcome. Cytokine. 2008;44(3):373–376. doi:10.1016/j.cyto.2008.10.007
   PubMed Web of Science ®Google Scholar
• Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine. 1992;4(1):1–5. doi:10.1016/1043-4666(92)90028-P
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res. 2001;33(5):251–255. doi:10.1159/000055677
   PubMed Web of Science ®Google Scholar
• Touzot M, Cacoub P, Bodaghi B, Soumelis V, Saadoun D. IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. Autoimmun Rev. 2015;14(5):370–375. doi:10.1016/j.autrev.2014.12.009
   PubMed Web of Science ®Google Scholar
• Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49(7):3058–3064. doi:10.1167/iovs.07-1390
   PubMed Web of Science ®Google Scholar
• Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet’s disease. Clin Exp Dermatol. 2005;30(1):61–63. doi:10.1111/j.1365-2230.2004.01684.x
   PubMed Web of Science ®Google Scholar
• Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S. Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behcet’s disease. J Dermatol. 2003;30(8):602–607. doi:10.1111/j.1346-8138.2003.tb00442.x
   PubMed Web of Science ®Google Scholar
• Kone-Paut I, Shahram F, Darce-Bello M, et al. Consensus classification criteria for paediatric Behcet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75(6):958–964. doi:10.1136/annrheumdis-2015-208491
   PubMed Web of Science ®Google Scholar
• Shahram F, Nadji A, Akhlaghi M, et al. Paediatric Behcet’s disease in Iran: report of 204 cases. Clin Exp Rheumatol. 2018;36(6 Suppl 115):135–140.
   PubMedGoogle Scholar
• Atmaca L, Boyvat A, Yalcindag FN, Atmaca-Sonmez P, Gurler A. Behcet disease in children. Ocul Immunol Inflamm. 2011;19(2):103–107. doi:10.3109/09273948.2011.555592
   PubMed Web of Science ®Google Scholar
• Makmur EL, Myers SH, Hanns L, Haskard DO, Brogan P, Ambrose N. Comparing the clinical profile of adults and children with Behcet’s syndrome in the UK. Clin Exp Rheumatol. 2019;37 Suppl 121(6):48–51.
   PubMed Web of Science ®Google Scholar
• Krause I, Uziel Y, Guedj D, et al. Childhood Behcet’s disease: clinical features and comparison with adult-onset disease. Rheumatology. 1999;38(5):457–462. doi:10.1093/rheumatology/38.5.457
   PubMed Web of Science ®Google Scholar
• Main DM, Chamberlain MA. Clinical differentiation of oral ulceration in Behcet’s disease. Br J Rheumatol. 1992;31(11):767–770. doi:10.1093/rheumatology/31.11.767
   PubMedGoogle Scholar
• Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J. 2007;48(4):573–585. doi:10.3349/ymj.2007.48.4.573
   PubMed Web of Science ®Google Scholar
• Mendes D, Correia M, Barbedo M, et al. Behcet’s disease–a contemporary review. J Autoimmun. 2009;32(3–4):178–188. doi:10.1016/j.jaut.2009.02.011
   PubMed Web of Science ®Google Scholar
• Citirik M, Berker N, Songur MS, Soykan E, Zilelioglu O. Ocular findings in childhood-onset Behcet disease. J AAPOS. 2009;13(4):391–395. doi:10.1016/j.jaapos.2009.04.016
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behcet disease:a descriptive study of 36 cases. Am J Ophthalmol. 2003;136(6):1114–1119. doi:10.1016/S0002-9394(03)00791-8
   PubMed Web of Science ®Google Scholar
• Hazleman BL. Rheumatic disorders of the eye and the various structures involved. Br J Rheumatol. 1996;35(3):258–268. doi:10.1093/rheumatology/35.3.258
   PubMedGoogle Scholar
• Reiff A, Kadayifcilar S, Ozen S. Rheumatic inflammatory eye diseases of childhood. Rheum Dis Clin North Am. 2013;39(4):801–832. doi:10.1016/j.rdc.2013.05.005
   PubMed Web of Science ®Google Scholar
• Accorinti M, Pesci FR, Pirraglia MP, Abicca I, Pivetti-Pezzi P. Ocular Behcet’s disease: changing patterns over time, complications and long-term visual prognosis. Ocul Immunol Inflamm. 2017;25(1):29–36. doi:10.3109/09273948.2015.1094095
   PubMed Web of Science ®Google Scholar
• Metreau-Vastel J, Mikaeloff Y, Tardieu M, Kone-Paut I, Tran TA. Neurological involvement in paediatric Behcet’s disease. Neuropediatrics. 2010;41(5):228–234. doi:10.1055/s-0030-1269909
   PubMed Web of Science ®Google Scholar
• Mora P, Menozzi C, Orsoni JG, Rubino P, Ruffini L, Carta A. Neuro-Behcet’s disease in childhood: a focus on the neuro-ophthalmological features. Orphanet J Rare Dis. 2013;8(1):18. doi:10.1186/1750-1172-8-18
   PubMed Web of Science ®Google Scholar
• Noel N, Bernard R, Wechsler B, et al. Long-term outcome of neuro-Behcet’s disease. Arthritis Rheumatol. 2014;66(5):1306–1314. doi:10.1002/art.38351
   PubMed Web of Science ®Google Scholar
• Siva A, Saip S. The spectrum of nervous system involvement in Behcet’s syndrome and its differential diagnosis. J Neurol. 2009;256(4):513–529. doi:10.1007/s00415-009-0145-6
   PubMed Web of Science ®Google Scholar
• Seyahi E. Behcet’s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016;30(2):279–295. doi:10.1016/j.berh.2016.08.002
   PubMed Web of Science ®Google Scholar
• Wu X, Li G, Huang X, et al. Behcet’s disease complicated with thrombosis: a report of 93 Chinese cases. Medicine. 2014;93(28):e263. doi:10.1097/MD.0000000000000263
   PubMed Web of Science ®Google Scholar
• Emmi G, Bettiol A, Silvestri E, et al. Vascular Behcet’s syndrome: an update. Intern Emerg Med. 2019;14(5):645–652. doi:10.1007/s11739-018-1991-y
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Bersani G, et al. PFAPA syndrome and Behcet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clin Rheumatol. 2016;35(2):501–505. doi:10.1007/s10067-015-2890-5
   PubMed Web of Science ®Google Scholar
• Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine. 2012;91(1):35–48. doi:10.1097/MD.0b013e318242ff37
   PubMed Web of Science ®Google Scholar
• Geri G, Wechsler B, Thi Huong du L, et al. Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature. Medicine. 2012;91(1):25–34. doi:10.1097/MD.0b013e3182428f49
   PubMed Web of Science ®Google Scholar
• Ozen S. The “other” vasculitis syndromes and kidney involvement. Pediatr Nephrol. 2010;25(9):1633–1639. doi:10.1007/s00467-009-1327-2
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behcet’s disease. Arthritis Rheum. 2010;62(9):2806–2812. doi:10.1002/art.27568
   PubMed Web of Science ®Google Scholar
• Disease ISGfBs. Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet. 1990;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Assaad‐Khalil S, Calamia K.T,et al. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–347. doi:10.1111/jdv.12107
   PubMed Web of Science ®Google Scholar
• Davatchi F. Diagnosis/classification criteria for Behcet’s disease. Patholog Res Int. 2012;2012:607921.
   PubMedGoogle Scholar
• Batu ED, Sonmez HE, Sozeri B, Butbul Aviel Y, Bilginer Y, Ozen S. The performance of different classification criteria in paediatric Behcet’s disease. Clin Exp Rheumatol. 2017;35 Suppl 108(6):119–123.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77(6):808–818. doi:10.1136/annrheumdis-2018-213225
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Rigante D. Biological treatments in Behcet’s disease: beyond anti-TNF therapy. Mediators Inflamm. 2014;2014:107421. doi:10.1155/2014/107421
   PubMed Web of Science ®Google Scholar
• Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behcet’s syndrome. Semin Arthritis Rheum. 2019;48(4):752–762. doi:10.1016/j.semarthrit.2018.05.008
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum. 2001;44(11):2686–2692. doi:10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Scherrer MAR, Rocha VB, Garcia LC. Behcet’s disease: review with emphasis on dermatological aspects. An Bras Dermatol. 2017;92(4):452–464. doi:10.1590/abd1806-4841.20177359
   PubMed Web of Science ®Google Scholar
• Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behcet’s disease: a review. World J Gastroenterol. 2015;21(13):3801–3812. doi:10.3748/wjg.v21.i13.3801
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behcet’s disease. Arthritis Care Res. 2010;62(12):1733–1738. doi:10.1002/acr.20308
   PubMed Web of Science ®Google Scholar
• Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology. 1999;106(3):586–589. doi:10.1016/S0161-6420(99)90120-3
   PubMed Web of Science ®Google Scholar
• Ozguler Y, Leccese P, Christensen R, et al. Management of major organ involvement of Behcet’s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology. 2018;57(12):2200–2212. doi:10.1093/rheumatology/key242
   PubMed Web of Science ®Google Scholar
• Shugaiv E, Tuzun E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet’s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S64–7.
   PubMed Web of Science ®Google Scholar
• Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous adamantiades-Behcet’s disease. Dermatology. 2001;203(4):322–324. doi:10.1159/000051781
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320–335. doi:10.1016/j.semarthrit.2003.09.010
   PubMed Web of Science ®Google Scholar
• Poddighe D, Mukusheva Z, Dauyey K, Assylbekova M. Adalimumab in the treatment of pediatric Behçet’s disease: case-based review. Rheumatol Int. 2019;39(6):1107–1112. doi:10.1007/s00296-019-04300-0
   PubMed Web of Science ®Google Scholar
• Nanthapisal S, Klein NJ, Ambrose N, Eleftheriou D, Brogan PA. Paediatric Behçet’s disease: a UK tertiary centre experience. Clin Rheumatol. 2016;35(10):2509–2516. doi:10.1007/s10067-016-3187-z
   PubMed Web of Science ®Google Scholar
• Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R. Successful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease. Rheumatology. 2015;54(7):1327–1328. doi:10.1093/rheumatology/kev197
   PubMed Web of Science ®Google Scholar
• McNally TW, Damato EM, Murray PI, Denniston AK, Barry RJ. An update on the use of biologic therapies in the management of uveitis in Behcet’s disease: a comprehensive review. Orphanet J Rare Dis. 2017;12(1):130. doi:10.1186/s13023-017-0681-6
   PubMed Web of Science ®Google Scholar
• Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet’s disease. Clin Gastroenterol Hepatol. 2015;13(5):940–8.e3. doi:10.1016/j.cgh.2014.08.042
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behcet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183–189. doi:10.1007/s10067-016-3480-x
   PubMed Web of Science ®Google Scholar
• Park J, Cheon JH. Anti-tumor necrosis factor therapy in intestinal Behcet’s disease. Gut Liver. 2018;12(6):623–632. doi:10.5009/gnl17462
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98–105.
   PubMed Web of Science ®Google Scholar
• Bettiol A, Silvestri E, Di Scala G, et al. The right place of interleukin-1 inhibitors in the treatment of Behcet’s syndrome: a systematic review. Rheumatol Int. 2019;39(6):971–990. doi:10.1007/s00296-019-04259-y
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191–197. doi:10.1007/s10067-016-3506-4
   PubMed Web of Science ®Google Scholar
• Essaadouni L, Ha-Ou-Nou FZ. Efficacy and safety of tocilizumab in neuro-Behcet’s disease: a case report. Revue Neurologique. 2017;173(3):171–172. doi:10.1016/j.neurol.2017.02.006
   PubMed Web of Science ®Google Scholar
• Kurtuncu M, Tuzun E, Akman-Demir G. Behcet’s disease and nervous system involvement. Curr Treat Options Neurol. 2016;18(5):19. doi:10.1007/s11940-016-0405-6
   PubMed Web of Science ®Google Scholar
• Sota J, Rigante D, Lopalco G, et al. Biological therapies for the treatment of Behcet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatol Int. 2018;38(1):25–35. doi:10.1007/s00296-017-3775-5
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, Emmi L, Cantarini L, Prisco D. Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behcets disease. Semin Arthritis Rheum. 2016;46(1):e1–2. doi:10.1016/j.semarthrit.2016.03.006
   PubMedGoogle Scholar
• Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Behcet’s disease treated with tocilizumab. Clin Rheumatol. 2015;34(6):1141–1143. doi:10.1007/s10067-014-2589-z
   PubMed Web of Science ®Google Scholar
• Di Scala G, Bettiol A, Cojan RD, Finocchi M, Silvestri E, Emmi G. Efficacy of the anti-IL 17 secukinumab in refractory Behcet’s syndrome: a preliminary study. J Autoimmun. 2019;97:108–113. doi:10.1016/j.jaut.2018.09.002
   PubMed Web of Science ®Google Scholar
• Mirouse A, Barete S, Desbois AC, et al. Long-term outcome of ustekinumab therapy for Behcet’s disease. Arthritis Rheumatol. 2019;71(10):1727–1732. doi:10.1002/art.40912
   PubMed Web of Science ®Google Scholar
• Lopalco G, Fabiani C, Venerito V, Lapadula G, Iannone F, Cantarini L. Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behcet’s disease. Clin Exp Rheumatol. 2017;35 Suppl 108(6):130–131.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DR. Alemtuzumab as remission induction therapy in Behcet disease: a 20-year experience. J Rheumatol. 2015;42(10):1906–1913. doi:10.3899/jrheum.141344
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, et al. A doublemasked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet’s disease. Ocul Immunol Inflamm. 2007;15(2):63–70. doi:10.1080/09273940701299370
   PubMed Web of Science ®Google Scholar
• Jade J, Chung K, Arendse M, Hussain Z, White D. Neuro-Behcet’s disease presenting with tumour-like lesions and responding to rituximab. J Clin Neurosci. 2016;32:139–141. doi:10.1016/j.jocn.2016.03.020
   PubMed Web of Science ®Google Scholar
• Kidd DP. Rituximab is effective in severe treatment-resistant neurological Behcet’s syndrome. J Neurol. 2015;262(12):2676–2677. doi:10.1007/s00415-015-7897-y
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246–252. doi:10.1111/j.1756-185X.2010.01546.x
   PubMed Web of Science ®Google Scholar
• Takeno M. Positioning of apremilast in treatment of Behcet’s disease. Modern Rheumatol. 2020;30(2):219–224. doi:10.1080/14397595.2019.1696504
   PubMed Web of Science ®Google Scholar